Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

Statement on the World Health Organization’s Declaration of a Public Health Emergency International Concern for Zika Virus

WASHINGTON, D.C. — Feb. 8, 2016 — On Monday, the World Health Organization (WHO) Director-General, Dr. Margaret Chan, declared Zika a Public Health Emergency International Concern (PHEIC), because of growing concerns of the suspected association between Zika and the rise in detected cases of congenital malformations and neurological complications in newborn babies.